Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H22N6O2 |
Molecular Weight | 414.4598 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(NCC#N)C1=CC=C(C=C1)C2=NC(NC3=CC=C(C=C3)N4CCOCC4)=NC=C2
InChI
InChIKey=ZVHNDZWQTBEVRY-UHFFFAOYSA-N
InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)
DescriptionSources: http://adisinsight.springer.com/drugs/800030557Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19295546 | https://www.ncbi.nlm.nih.gov/pubmed/23459451
Sources: http://adisinsight.springer.com/drugs/800030557
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19295546 | https://www.ncbi.nlm.nih.gov/pubmed/23459451
Momelotinib (CYT387) is an ATP-competitive small molecule that potently inhibits JAK1/JAK2 kinases. Momelotinib is developing by Gilead Sciences for the oral treatment of pancreatic and non-small cell lung cancers, and myeloproliferative disorders (including myelofibrosis, essential thrombocythaemia and polycythaemia vera).
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23827160
Curator's Comment: Momelotinib (CYT387) is brain penetrant in mice. No human data available.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2835 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19295546 |
11.0 nM [IC50] | ||
Target ID: CHEMBL2971 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19295546 |
18.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator​
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [IC50 5.8048 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). | 2009 Oct 15 |
|
CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. | 2010 Jun 24 |
|
Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. | 2014 May 6 |
Patents
Sample Use Guides
150-300 mg/day. Maximum tolerated dose of momelotinib was found to be 300 mg/day in the phase I portion of a phase I/II study (NCT00935987) in patients with myelofibrosis. At the higher dose level of 400 mg/day, two of six patients experienced dose-limiting toxicities.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20385788
0.5 and 1.5 uM CYT387 caused growth suppression and apoptosis in JAK2-dependent hematopoietic cell lines, while nonhematopoietic cell lines were unaffected.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1967
Created by
admin on Sat Dec 16 17:21:48 GMT 2023 , Edited by admin on Sat Dec 16 17:21:48 GMT 2023
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 17:21:48 GMT 2023 , Edited by admin on Sat Dec 16 17:21:48 GMT 2023
|
||
|
FDA ORPHAN DRUG |
311610
Created by
admin on Sat Dec 16 17:21:48 GMT 2023 , Edited by admin on Sat Dec 16 17:21:48 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB11763
Created by
admin on Sat Dec 16 17:21:48 GMT 2023 , Edited by admin on Sat Dec 16 17:21:48 GMT 2023
|
PRIMARY | |||
|
C88311
Created by
admin on Sat Dec 16 17:21:48 GMT 2023 , Edited by admin on Sat Dec 16 17:21:48 GMT 2023
|
PRIMARY | |||
|
XX-160
Created by
admin on Sat Dec 16 17:21:48 GMT 2023 , Edited by admin on Sat Dec 16 17:21:48 GMT 2023
|
PRIMARY | |||
|
9480
Created by
admin on Sat Dec 16 17:21:48 GMT 2023 , Edited by admin on Sat Dec 16 17:21:48 GMT 2023
|
PRIMARY | |||
|
6O01GMS00P
Created by
admin on Sat Dec 16 17:21:48 GMT 2023 , Edited by admin on Sat Dec 16 17:21:48 GMT 2023
|
PRIMARY | |||
|
DTXSID801026049
Created by
admin on Sat Dec 16 17:21:48 GMT 2023 , Edited by admin on Sat Dec 16 17:21:48 GMT 2023
|
PRIMARY | |||
|
100000163080
Created by
admin on Sat Dec 16 17:21:48 GMT 2023 , Edited by admin on Sat Dec 16 17:21:48 GMT 2023
|
PRIMARY | |||
|
25062766
Created by
admin on Sat Dec 16 17:21:48 GMT 2023 , Edited by admin on Sat Dec 16 17:21:48 GMT 2023
|
PRIMARY | |||
|
CYT387
Created by
admin on Sat Dec 16 17:21:48 GMT 2023 , Edited by admin on Sat Dec 16 17:21:48 GMT 2023
|
PRIMARY | |||
|
CHEMBL1078178
Created by
admin on Sat Dec 16 17:21:48 GMT 2023 , Edited by admin on Sat Dec 16 17:21:48 GMT 2023
|
PRIMARY | |||
|
91407
Created by
admin on Sat Dec 16 17:21:48 GMT 2023 , Edited by admin on Sat Dec 16 17:21:48 GMT 2023
|
PRIMARY | |||
|
1056634-68-4
Created by
admin on Sat Dec 16 17:21:48 GMT 2023 , Edited by admin on Sat Dec 16 17:21:48 GMT 2023
|
PRIMARY | |||
|
SUB177206
Created by
admin on Sat Dec 16 17:21:48 GMT 2023 , Edited by admin on Sat Dec 16 17:21:48 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE ACTIVE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)